OTC · Biotechnology

hVIVO plc (OPORF) Stock

$0.11 +0.00% OTC: OPORF Healthcare

hVIVO plc functions as a contract research organization and pharmaceutical service provider, primarily dedicated to evaluating vaccines and antiviral medications. This is achieved through specialized human challenge clinical trials.

Valuation

MetricValue
Price$0.11
Market Cap$75.45M
P/E Ratio-8.81
P/B Ratio1.39
P/S Ratio1.11
EPS (TTM)$-0.01
52-Week High$0.35
52-Week Low$0.09
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-14.65%
ROA-8.35%
ROCE-11.66%
Gross Margin-6.07%
Operating Margin-13.13%
Net Margin-12.48%
Debt/Equity0.39
Current Ratio1.63

Annual Financials (USD)

Metric20212022202320242025
Revenue$37.0M$51.0M$56.0M$63.0M$47.0M
Operating Profit$1.0M$6.0M$10.0M$13.0M$0
Net Profit$0$-1.0M$16.0M$11.0M$-6.0M
EPS$0.00$0.00$0.02$0.02$-0.01
Op Margin1.6%11.9%18.0%20.5%-0.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$42.0M$51.0M$83.0M$89.0M$72.0M
Total Liabilities$22.0M$31.0M$49.0M$44.0M$34.0M
Cash$16.0M$28.0M$37.0M$44.0M$14.0M
Borrowings$3.0M$2.0M$13.0M$13.0M$15.0M

Latest News

hVIVO order book tops £65m as CEO backs strong H2 recovery Proactive · Jul 22, 2026 Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London PR Newswire · Jun 8, 2026 Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic PR Newswire · Jun 1, 2026 S&U, 88 Energy, Serval Resources, Shoe Zone, hVIVO - Small Cap Snapshot Proactive · May 20, 2026 hVIVO, Bango, Light Science Technologies, Active Energy, Seeing Machines, Foresight Solar Fund Proactive · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$16.0M$17.0M$10.0M$-13.0M
Investing Cash Flow$-1.0M$-3.0M$-9.0M$-3.0M$-13.0M
Financing Cash Flow$-1.0M$-2.0M$0$0$-3.0M
Net Cash Flow$-4.0M$13.0M$9.0M$7.0M$-27.0M
Free Cash Flow$-2.0M$15.0M$12.0M$8.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.06
EV / EBITDA-253.97
FCF Yield-29.04%
Quick Ratio1.59
Interest Coverage-65.67
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held3.16%
Institutions Held30.79%
Institutions Float Held31.80%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BHCCFBenchmark Holdings plc $0.37 +0.00% -4.13 $225.11M 0.00%
EVGRFChina Evergrande New Energy Vehicle Group Limited $0.00 — -0.13 $2.17M 0.00%
FGHQFFrontage Holdings Corporation $0.15 +11.11% 44.83 $304.16M 0.00%
GNFTFGenfit S.a. $15.95 +0.00% -8.14 $799.03M 0.00%
HNSBFHansa Biopharma AB $2.90 +0.00% -4.72 $289.23M 0.00%

About hVIVO plc

hVIVO plc functions as a contract research organization and pharmaceutical service provider, primarily dedicated to evaluating vaccines and antiviral medications. This is achieved through specialized human challenge clinical trials. The company extends its services to a varied clientele, encompassing major pharmaceutical and biotechnology firms, governmental bodies, and public health agencies. A significant aspect of its operations is a comprehensive array of human challenge study models. These cover conditions such as respiratory syncytial virus (RSV), influenza, human rhinovirus, asthma, malaria, chronic cough, and chronic obstructive pulmonary disease (COPD), with a COVID-19 model currently being developed. Additionally, hVIVO is constructing the 'Disease in Motion' platform, an extensive database focused on infectious disease progression. This platform uniquely integrates diverse datasets, including clinical, immunological, virological, and digital (wearable) biomarkers. The 'Disease in Motion' platform holds broad potential applications for various end-users, from large technology and wearables companies to pharmaceutical and biotech sectors. Further capabilities include offering pre-clinical and early clinical research services, sales and marketing support, and expertise in biometry, data management, and statistics to its European pharmaceutical clients. The company also delivers drug development consultancy, covering Chemistry, Manufacturing, and Controls (CMC), pharmacokinetics (PK), and medical writing for a range of European clients. Formerly known as Open Orphan Plc, the company changed its name to hVIVO plc in October 2022 and is headquartered in London, United Kingdom.

hVIVO plc is headquartered in GB.

hVIVO plc (OPORF) stock trades at $0.11 with a market capitalization of $75.45M. The stock is valued at a price-to-earnings (P/E) ratio of -8.81, price-to-book of 1.39, price-to-sales of 1.11. Over the past 52 weeks the stock has ranged between $0.09 and $0.35, and currently trades 68.6% below its 52-week high.

On profitability, hVIVO plc generates a return on equity (ROE) of -14.65%, return on capital employed of -11.66%, an operating margin of -13.13%, a net profit margin of -12.48%.

Official website: www.hvivo.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides